ナノボディ市場は、予測期間中に 17.88% という堅調な CAGR を記録すると予想されます。持続性疾患の蔓延、正確な治療に対する関心の高まり、ナノボディの革新的な研究への関心の拡大が市場の発展を推進しています。
ナノボディは、より優れた強度、より優れた組織浸潤性、および免疫原性の低下など、従来の抗体よりもいくつか優れた機能を持つ、小さな対抗作用物質の部分です。免疫系疾患が一般的な疾患になりつつあることやその他の現在進行中の問題により、その治療のためのより新鮮でより実行可能なナノボディベースの薬剤の出現が求められています。 たとえば、2019年2月、米国FDAは、血栓性血小板減少性紫斑病（aTTP）に罹患した成人向けに、Sanofi S.A.（フランス）の主力ナノボディベース医薬品であるCablivi (caplacizumab-yhdp)を承認しました。
WHO によると、国際的な死亡者数の 74% は、悪性腫瘍、心血管疾患、糖尿病などの進行中の感染症によるものと考えられます。これらの病気の割合と蔓延は、人口の成熟、生活様式の進化、都市化の拡大などの変数によって増加し続けると考えられています。その結果、進行中の病気の蔓延の増加と、ナノボディの卓越した利点が市場の発展を推進しています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
4.2.2 RISING DEMAND FOR PRECISION MEDICINE
4.2.3 INCREASING INVESTMENT IN NANOBODY RESEARCH AND DEVELOPMENT
4.3 RESTRAINTS
4.3.1 MANUFACTURING CHALLENGES AND HIGH PRODUCTION COSTS
4.4 OPPORTUNITY
4.4.1 GROWING DEVELOPMENT OF NEW APPLICATIONS OF NANOBODIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL NANOBODY MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON CLINICAL TRIALS
5.3.3 IMPACT ON DEMAND AND SUPPLY
6 GLOBAL NANOBODY MARKET, BY TYPE
6.1 OVERVIEW
6.2 MONO-SPECIFIC
6.3 MULTI-SPECIFIC
7 GLOBAL NANOBODY MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 THERAPEUTIC
7.2.1 CANCER
7.2.2 NEURODEGENERATIVE DISEASES
7.2.3 INFECTIOUS DISEASES
7.2.4 OTHERS
7.3 DIAGNOSTIC
7.3.1 DETECTION OF PROTEINS AND MICROORGANISMS
7.3.2 DETECTION OF SMALL MOLECULES
7.3.3 IMAGING
7.4 RESEARCH
8 GLOBAL NANOBODY MARKET, BY END USER
8.1 OVERVIEW
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3 RESEARCH LABORATORIES
8.4 OTHERS
9 GLOBAL NANOBODY MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL NANOBODY MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL NANOBODY MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
10.6.2 MERGER/ ACQUISITION
10.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION
10.7 MAJOR PLAYERS SALES ANALYSIS
10.8 MAJOR PLAYERS R&D ANALYSIS
11 COMPANY PROFILES
11.1 SANOFI
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 MERCK KGAA
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 BIOCYTOGEN
11.3.1 COMPANY OVERVIEWS
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 PROTEINTECH GROUP, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 NOVARTIS AG
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTSS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 GENSCRIPT
11.6.1 COMPANY OVERVIEWS
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 SENSEI BIOTHERAPEUTICS, INC
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 BERONI GROUP
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 EXEVIR BIO
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
11.11 DIOSCURE THERAPEUTICS SE
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
